Pfizer creates breaking news with Allergan purchase

Posted on 23 November 2015

US drugs giant Pfizer has sealed a deal to buy Botox-maker Allergan for $160bn (£106bn) in what is the biggest pharmaceuticals deal in history.

Tags: , , ,

When de-risking, relationships matter: How using key strategies can get you to your next innovative partnership

Posted on 10 August 2015

An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration.

Tags: , , , ,

Boehringer Ingelheim acquires Pharmaxis’ anti-inflammatory candidate

Posted on 18 May 2015

Boehringer Ingelheim exercises option and acquires global ownership of Pharmaxis’ investigational anti-inflammatory drug candidate PXS4728A, including associated intellectual property rights.

Tags: ,

Endo International acquires Par Pharmaceutical

Posted on 18 May 2015

Endo International and Par Pharmaceutical Holdings have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05 billion, including assumption of Par debt.

Tags: , ,

Sorrento Sells Cynviloq for $1.3B to NantPharma

Posted on 15 May 2015

Sorrento Therapeutics agreed to sell its drug candidate Cynviloq (paclitaxel nanoparticle polymeric micelle) for up to $1.3 billion to NantPharma.

Tags: ,

Agilis Biotherapeutics enters license agreement with the University of South Florida

Posted on 13 May 2015

Agilis Biotherapeutics has entered into an exclusive worldwide license agreement with the University of South Florida for the treatment of using gene therapy technology developed by Edwin Weeber, PhD, Director of the Neurobiology of Learning and Memory and Chief Scientific Officer at the USF Health Byrd Alzheimer’s Research Institute at the University of South Florida, more »

Tags: , ,

Pfizer in asset purchase and option to acquire AM-Pharma

Posted on 12 May 2015

Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company.

Tags: ,

Adaptimmune closes its initial public offering of $175.7 million

Posted on 11 May 2015

Adaptimmune announced the closing of its initial public offering of 11,250,000 American Depositary Shares at a price to the public of $17.00 per ADS.

Tags: ,

Morphosys acquires Lanthio Pharma

Posted on 07 May 2015

MorphoSys has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.

Tags: ,

Transition Therapeutics licenses drug candidate from Eli Lilly

Posted on 06 May 2015

Transition Therapeutics announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate (“TT701”) from Eli Lilly and Company.

Tags: ,